Linda Rubinstein Email and Phone Number
I have over 35 years of operational, financial, capital markets and transactional experience in life sciences and SaaS, with particular expertise in biotechnology, life science tools and diagnostics. As CFO, I have overseen finance at R&D- and commercial-stage enterprises, consummated financing and M&A transactions, and contributed to operations and strategy at private and public companies. As an investment banker, I completed over 30 transactions, raising over $5 billion in capital for companies ranging from emerging start-ups to Fortune 500 companies. I am a partner of FLG Partners, a leading CFO services and board advisory firm. I have served as interim and full-time CFO for companies such as:PUBLIC* Adverum, a biotech company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases* Alector, a biotech company pioneering immuno-neurology and innate immuno-oncology* Five Prime, a biotech company with multiple clinical-stage immuno-oncology programs* Solexa, manufacturing and selling genetic analysis instrumentation* Prepared multiple VC-backed companies for IPOVENTURE BACKED* Sublimity Therapeutics, a biotech company developing an orally dosed calcineurin inhibitor for ulcerative colitis and advancing its proprietary SmPill® formulation technology * Apexigen, a biotech company developing antibody therapeutics to activate immunity in cancer* Kezar Life Sciences, a biotech company developing small molecule therapeutics for autoimmunity and cancer* True North, a biotech company developing novel therapies that selectively target the Complement pathway * PaxVax, a specialty vaccine company, where I executed financings totaling up to $62 million, was instrumental in the acquisition of vaccine assets from J&J / Crucell and designed the company's international tax structureACQUIRED* ArmaGen, a biotech company delivering protein drugs across the blood brain barrier to address orphan and neurodegenerative diseases; sold to JCR Pharmaceuticals * iPierian, a biotechnology company developing novel therapies for neurodegenerative disease; sold to BMS * Ingenuity Systems, a SaaS company serving life science research and diagnostics; sold to QIAGEN * Solexa -- see aboveI capped a decade in investment banking as SVP of Lehman Brothers’ Healthcare Investment Banking Group. Current and former board seats include Biocept, a molecular diagnostics company, and Sensorin, an analytical instrument company.Contact me at linda@flgpartners.com.
-
PartnerFlg Partners Sep 2010 - PresentPalo Alto, Ca, UsFLG is engaged by companies, their boards and investors to provide CFO leadership on a permanent, full time, part time, or project basis, from A-round private companies to billion-dollar public ones. We work with venture-backed companies, firms owned by private equity investors and public companies, across all sectors. My focus is life sciences, including biotechnology and molecular diagnostics, as well as healthcare in general. I'm also interested in greentech. I work with both public and private companies and have run IPO preparation, M&A and dual track processes.
-
CfoAdverum Biotechnologies Dec 2022 - PresentRedwood City, California, UsPublicly traded clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases -
Board MemberBiocept, Inc. Jul 2021 - Oct 2023San Diego, California, UsPublicly traded provider of molecular diagnostic assays and services, including CNSide, Biocept's cell-based and cell-free CSF liquid biopsy test. -
Consulting CfoMedikine, Inc. Sep 2022 - May 2023Menlo Park, UsClinical-stage biopharmaceutical company aiming to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing its versatile PEPTIKINE (synthetic cytokine) drug discovery platform -
Senior Financial AdvisorApexigen Nov 2018 - Jun 2022San Carlos, California, UsVenture-funded, clinical-stage biotech company developing antibody therapeutics to activate immunity in cancer. -
Interim CfoAlector Sep 2021 - Feb 2022South San Francisco, California, UsPublicly traded, clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. -
AdvisorRenovorx Jan 2021 - Aug 2021Los Altos, Ca, UsAdvised on execution of IPO for this Phase 3 biopharmaceutical company targeting difficult-to-treat solid tumors, initially pancreatic cancer and hilar cholangiocarcinoma, via its proprietary Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform. -
Consulting CfoSublimity Therapeutics Jan 2020 - Apr 2021Dublin, 11, IeVenture-funded, clinical-stage biotech company developing an orally dosed calcineurin inhibitor for ulcerative colitis (currently in Phase 2b) and advancing its proprietary SmPill® formulation technology. -
Consulting CfoArmagen Technologies 2015 - Apr 2020Calabasas, Ca, UsVenture-backed, clinical-stage biotech company with drug candidate pipeline in orphan and neurodegenerative diseases based on its blood brain barrier technology. Acquired by JCR Pharmaceuticals April 2020. -
Consulting CfoFive Prime Therapeutics, Inc. Apr 2018 - Nov 2018Interim CFO at publicly traded biotech company with multiple clinical-stage immuno-oncology programs.
-
Consulting CfoKezar Life Sciences Oct 2017 - Mar 2018South San Francisco, California, UsVenture-funded biotech company developing small molecule therapeutics for autoimmunity and cancer. Helped to prepare for IPO including completing PCAOB audit uplift and filing initial confidential S-1. -
Consulting CfoEpibiome 2015 - 2018Precision microbiome engineering company employing genomics and selective deletion strategies with initial application in bovine mastitis.
-
Consulting CfoRetrotope 2015 - 2017Clinical-stage biotech company addressing lipid peroxidation and mitochondrial ioss of function in multiple orphan indications and in major diseases including Alzheimer’s, Parkinson’s and retinopathies.
-
Consulting CfoTunitas Therapeutics 2014 - 2017Venture-backed biotechnology company developing novel therapeutics to address allergic inflammation, allergy and orphan diseases.
-
Consulting CfoTrue North Therapeutics Sep 2013 - Jul 2016Venture-backed biotechnology company developing novel therapies that selectively target the Complement pathway of the immune system. -
Board Of DirectorsSensorin 2007 - 2015Solid-state and internally calibrated pH sensing for process and other in-line applications.
-
Evp & CfoPaxvax, Inc. Feb 2014 - Oct 2014Specialty vaccine company addressing vaccines for travel and biodefense, with a double bottom line mission. I executed financings totaling up to $62 million, was instrumental in the acquisition of vaccine assets from J&J / Crucell and designed the company's international tax structure.
-
Consulting CfoIpierian Sep 2013 - Apr 2014Biotechnology company developing novel therapies for neurodegenerative disease, including PSP and Alzheimer's, which was acquired by Bristol-Myers Squibb in 2014.
-
Svp & CfoIngenuity Systems Nov 2010 - May 2013Cloud computing for genome analysis for research and diagnostics, which was acquired by QIAGEN in 2013.
-
Consulting CfoMedallia, Inc. 2010 - 2010Pleasanton, California, UsSaaS for customer experience management used by hundreds of the world’s leading brands. -
ConsultantSignum Biosciences 2010 - 2010Princeton, New Jersey, Us -
Consulting CfoAmplyx Pharmaceuticals, Inc 2009 - 2010San Diego, Ca, Us -
PartnerRdj Advisors 2007 - 2010Financial and strategic consultants to the biotechnology and medical device industries:• Interim and long-term consulting CFO• Plan and execute equity and debt financings• Corporate development, including M&A• Create business plans
-
Consulting CfoIngenuity Systems 2009 - 2009
-
Vice President And CfoSolexa 2005 - 2007San Diego, Ca, UsAcquired by Illumina, Inc. -
PartnerRdj Advisors 2004 - 2005
-
Consulting CfoIngenuity Systems 2004 - 2005
-
ContractorBiotechnology Industry Organization 2004 - 2005Washington, Dc, Us -
Vice President Of FinanceChemocentryx 2001 - 2003San Carlos, California, Us -
ConsultantPlexxikon Inc. 2001 - 2001South San Francisco, California, Us -
Senior Vice President, Investment BankingLehman Brothers 1993 - 2001Us• 1996-2001: Health care investment banking (San Francisco, CA)• 1993-1995: Industrial group investment banking (New York, NY) -
Associate, Investment BankingScully Brothers & Foss 1989 - 1993
-
Analyst, Investment BankingMerrill Lynch 1987 - 1989New York, Ny, Us -
Director Of Commercial DevelopmentAmerican-Israel Chamber Of Commerce 1985 - 1987
Linda Rubinstein Education Details
-
UclaEconomics
Frequently Asked Questions about Linda Rubinstein
What company does Linda Rubinstein work for?
Linda Rubinstein works for Flg Partners
What is Linda Rubinstein's role at the current company?
Linda Rubinstein's current role is Partner at FLG Partners | CFO at Adverum Biotechnologies.
What schools did Linda Rubinstein attend?
Linda Rubinstein attended Ucla.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial